Who to call at Debiopharm, and when
Fundz watches for the moments Debiopharm starts buying, and tells you who to reach.
- An alert the day Debiopharm raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Debiopharm, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Debiopharm. With Fundz connected, it knows.
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs
Contract Type
agreement
Description
ITM Isotope Technologies Munich SE (ITM) and Debiopharm have entered an agreement under which ITM gains the exclusive global license for the clinical and commercial development of the peptide-based, theranostic pair ITM-91/ITM-94D, targeting the Carbonic Anhydrase IX (CA IX) surface protein.
Quick answer
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs (September 12, 2024). Debiopharm is based in Lausanne, Vaud, Switzerland.
- What agreement did Debiopharm announce on September 12, 2024?
- ITM Isotope Technologies Munich SE (ITM) and Debiopharm have entered an agreement under which ITM gains the exclusive global license for the clinical and commercial development of the peptide-based, theranostic pair ITM-91/ITM-94D, targeting the Carbonic Anhydrase IX (CA IX) surface protein.
- What does Debiopharm do?
- Debiopharm is a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases.
- Where is Debiopharm based?
- Debiopharm is based in Lausanne, Vaud, Switzerland.
Source: Fundz verified event record.
Related People
Debiopharm signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.